TWiV 606: Evidence-based science and medicine for COVID-19
Apr 26, 2020•1 hr 54 min•Ep. 606
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler
Guest: Daniel Griffin
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Inactivated SARS-CoV-2 vaccine protects monkeys (bioRxiv)
- Saliva is more sensitve than nasopharyngeal swab (medRxiv)
- NY serological survey results (NY Times)
- FDA caveats on serological tests (FDA)
- Federal guidelines on when to open
- When to open: Roadmap, blog, video explainer
- Blocking TMPRSS2 blocks SARS-CoV-2 infection (Cell)
- Lawmakers want human challenge studies (Science)
- Letters read on TWiV 606
- Image credit
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees.
Send your virology questions and comments to twiv@microbe.tv
For the best experience, listen in Metacast app for iOS or Android